Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1b/2 Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Oct 2018

At a glance

  • Drugs BMS 813160 (Primary) ; Nivolumab (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Paclitaxel
  • Indications Colorectal cancer; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 06 Sep 2018 Planned End Date changed from 8 Mar 2021 to 20 Dec 2021.
    • 06 Sep 2018 Planned primary completion date changed from 8 Mar 2021 to 10 Dec 2020.
    • 14 Mar 2018 According to the Bristol-Myers Squibb media release, data from this trial will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top